Skip to main content
BAX
NYSE Industrial Applications And Services

Baxter Beats Q2 Estimates, Raises Full-Year Outlook on Broad-Based Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$27.69
Mkt Cap
$12.793B
52W Low
$15.73
52W High
$28.995
52W Position info
76% above low
Off High info
4.5% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

BAX sits 76% above its 52-week low of $15.73.

Summary

Baxter reported Q2 2026 sales of $2.96B (up 5% organic) and adjusted EPS of $0.56, beating expectations. The company raised its full-year guidance for sales growth and adjusted EPS to $1.95-$2.15.


Key Events · Earnings and Guidance · BAX

  • Q2 Beat Across the Board

    Sales of $2.96B grew 5% on both a reported and organic basis, exceeding expectations. Adjusted EPS of $0.56 included a $0.11 benefit from an IEEPA tariff refund, but even excluding that, results were ahead of prior implied guidance.

  • Full-Year Guidance Raised

    Baxter lifted its 2026 outlook: reported sales growth now 3-4% (from flat-1%), organic growth 2-3% (from ~flat), and adjusted EPS $1.95-$2.15 (from $1.85-$2.05). The raise reflects both the Q2 beat and improved second-half expectations.

  • Broad Segment Growth

    Medical Products & Therapies sales rose 7% reported (5% organic), driven by Infusion Therapies & Platforms. Healthcare Systems & Technologies grew 4% on both reported and organic bases, with strength in Care & Connectivity Solutions.

  • Dividend Maintained at $0.01

    The Board declared a quarterly cash dividend of $0.01 per share, payable October 1, 2026 to shareholders of record as of August 28, 2026. The dividend remains at the reduced level set after the Kidney Care sale.


Analysis · BAX · Industrial Applications And Services

A clean beat-and-raise quarter underscores Baxter's strengthening operating momentum. Organic sales rose 5%, with all segments contributing, and the company lifted its full-year sales and profit targets. Adjusted EPS of $0.56 topped the prior implied guidance, helped by a one-time tariff refund, but even excluding that benefit, core performance is improving. The raised outlook signals management confidence that stabilization efforts are taking hold, though the stock is already near its 52-week high, suggesting some optimism is priced in.

At the time of this filing, BAX was trading at $27.69 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.8B. The 52-week trading range was $15.73 to $29.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BAX - Latest Insights

BAX
Jul 30, 2026, 7:26 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $28.50
Real-time Price: $28.34 info
Change: -$0.165 (-0.58%) info
Market Cap: $12.793B info
BAX
Jul 30, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $25.20
Real-time Price: $28.34 info
Change: +$3.14 (+12%) info
Market Cap: $12.793B info
BAX
May 08, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $17.99
Real-time Price: $28.34 info
Change: +$10.35 (+58%) info
Market Cap: $12.793B info
BAX
May 08, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.01
Real-time Price: $28.34 info
Change: +$10.33 (+57%) info
Market Cap: $12.793B info
BAX
Apr 30, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $17.44
Real-time Price: $28.34 info
Change: +$10.90 (+62%) info
Market Cap: $12.793B info